dapsone has been researched along with Acquired Immune Deficiency Syndrome in 62 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the interaction between dapsone and trimethoprim in patients with the acquired immunodeficiency syndrome (AIDS)." | 9.06 | Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions. ( Benowitz, NL; Jacob, P; Lee, BL; Medina, I; Mills, J; Wofsy, CB, 1989) |
| " Numerous testing modalities are performed in the ED focused on an infectious versus pulmonary etiology prior to coming to the conclusion that the source is methemoglobinemia induced by dapsone therapy." | 7.91 | Neutropenia, Hypoxia, and the Complexities of Emergency Medicine: A Case of Dapsone-Induced Methemoglobinemia. ( Blomkalns, A; Iams, A; Vu, S, 2019) |
| "The efficacy, toxicity and cost of orally administered dapsone (50-100 mg/day) for prophylaxis of Pneumocystis carinii pneumonia (PCP) were evaluated in 30 patients with AIDS or AIDS-related complex (ARC)." | 7.68 | Low-dose dapsone prophylaxis of Pneumocystis carinii pneumonia in AIDS and AIDS-related complex. ( Deresinski, SC; Greene, SI; Kemper, CA; Kessinger, JM; Lang, OS; Stevens, DA; Tucker, RM, 1990) |
| "We have treated 113 patients with zidovudine since its licensure, 80 with acquired immunodeficiency syndrome and 33 with acquired immunodeficiency syndrome-related complex." | 7.67 | Clinical experience with zidovudine for patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex. ( Gor, D; Helbert, M; Janes, K; Jeffries, DJ; Kocsis, AE; Mitchell, D; Peddle, B; Pinching, AJ; Robinson, D; Stoneham, C, 1989) |
| "All patients with the acquired immunodeficiency syndrome and a first episode of Pneumocystis carinii pneumonia seen at the San Francisco General Hospital between November 1984 and April 1985 were evaluated for oral treatment with dapsone (100 mg/d) plus trimethoprim (20 mg/kg body weight X d)." | 7.67 | Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. ( Hopewell, PC; Hughes, W; Leoung, GS; Mills, J; Wofsy, C, 1986) |
| "All patients with the acquired immunodeficiency syndrome treated for their first episode of Pneumocystis carinii pneumonia at San Francisco General Hospital between 1 April 1985 and 15 July 1985 were evaluated for their response to treatment with dapsone (100 mg/day) by mouth for 21 days." | 7.67 | Dapsone treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. ( Hopewell, PC; Hughes, WT; Leoung, G; Medina, I; Mills, J; Wofsy, C, 1988) |
| "In patients with AIDS, oral therapy with trimethoprim-sulfamethoxazole and with trimethoprim-dapsone are equally effective for mild-to-moderate first episodes of P." | 6.67 | Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. ( Benowitz, N; Hopewell, PC; Lee, B; Leoung, G; Medina, I; Mills, J; Modin, G; Wofsy, CB, 1990) |
| "To examine the interaction between dapsone and trimethoprim in patients with the acquired immunodeficiency syndrome (AIDS)." | 5.06 | Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions. ( Benowitz, NL; Jacob, P; Lee, BL; Medina, I; Mills, J; Wofsy, CB, 1989) |
| " Numerous testing modalities are performed in the ED focused on an infectious versus pulmonary etiology prior to coming to the conclusion that the source is methemoglobinemia induced by dapsone therapy." | 3.91 | Neutropenia, Hypoxia, and the Complexities of Emergency Medicine: A Case of Dapsone-Induced Methemoglobinemia. ( Blomkalns, A; Iams, A; Vu, S, 2019) |
| "To investigate the relationship between high incidence of adverse dapsone reactions in acquired immunodeficiency syndrome (AIDS) patients and slow acetylate phenotype or low plasma/lymphocyte glutathione level of these patients." | 3.69 | Relationship between high incidence of adverse dapsone reactions and slow acetylate phenotype or low plasma/lymphocyte glutathione level. ( Guo, R; Lauterberg, B; Thormann, W, 1996) |
| "The efficacy, toxicity and cost of orally administered dapsone (50-100 mg/day) for prophylaxis of Pneumocystis carinii pneumonia (PCP) were evaluated in 30 patients with AIDS or AIDS-related complex (ARC)." | 3.68 | Low-dose dapsone prophylaxis of Pneumocystis carinii pneumonia in AIDS and AIDS-related complex. ( Deresinski, SC; Greene, SI; Kemper, CA; Kessinger, JM; Lang, OS; Stevens, DA; Tucker, RM, 1990) |
| "We have treated 113 patients with zidovudine since its licensure, 80 with acquired immunodeficiency syndrome and 33 with acquired immunodeficiency syndrome-related complex." | 3.67 | Clinical experience with zidovudine for patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex. ( Gor, D; Helbert, M; Janes, K; Jeffries, DJ; Kocsis, AE; Mitchell, D; Peddle, B; Pinching, AJ; Robinson, D; Stoneham, C, 1989) |
| "All patients with the acquired immunodeficiency syndrome and a first episode of Pneumocystis carinii pneumonia seen at the San Francisco General Hospital between November 1984 and April 1985 were evaluated for oral treatment with dapsone (100 mg/d) plus trimethoprim (20 mg/kg body weight X d)." | 3.67 | Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. ( Hopewell, PC; Hughes, W; Leoung, GS; Mills, J; Wofsy, C, 1986) |
| "A 44-year-old man with acquired immunodeficiency syndrome (AIDS) and Pneumocystis carinii pneumonia (PCP) who suffered adverse effects from treatment with trimethoprim-sulfamethoxazole (TMP-SMX) and was then treated with pentamidine isethionate is described, and approved and investigational drugs used in the management of PCP in the AIDS patient are discussed." | 3.67 | Treatment of Pneumocystis carinii pneumonia in patients with AIDS. ( Hauptman, SP; Wordell, CJ, 1988) |
| "All patients with the acquired immunodeficiency syndrome treated for their first episode of Pneumocystis carinii pneumonia at San Francisco General Hospital between 1 April 1985 and 15 July 1985 were evaluated for their response to treatment with dapsone (100 mg/day) by mouth for 21 days." | 3.67 | Dapsone treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. ( Hopewell, PC; Hughes, WT; Leoung, G; Medina, I; Mills, J; Wofsy, C, 1988) |
| "The test is applied on AIDS prophylaxis and paediatric trials." | 2.69 | Combining mortality and longitudinal measures in clinical trials. ( Finkelstein, DM; Schoenfeld, DA, 1999) |
| "The P." | 2.69 | Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. ( Armstrong, W; Burman, W; Crane, L; Hossler, PA; Katz, J; Kazanjian, P; Lee, CH; Meshnick, SR; Richardson, J, 2000) |
| "However, in AIDS patients with liver impairment and impaired glucuronidation, doses of zidovudine may need to be decreased." | 2.68 | Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection. ( Gambertoglio, JG; Lee, BL; Makrides, V; Safrin, S, 1996) |
| " Six patients had received oral dapsone for at least 1 month at the dosage regimen of 100 mg twice of three times weekly and four patients had received a single oral 100 mg dose." | 2.68 | Penetration of dapsone into cerebrospinal fluid of patients with AIDS. ( Bassetti, M; Cruciani, M; Gatti, G; Hossein, J; Malena, M, 1997) |
| "In patients with AIDS, oral therapy with trimethoprim-sulfamethoxazole and with trimethoprim-dapsone are equally effective for mild-to-moderate first episodes of P." | 2.67 | Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. ( Benowitz, N; Hopewell, PC; Lee, B; Leoung, G; Medina, I; Mills, J; Modin, G; Wofsy, CB, 1990) |
| "In addition, patients with AIDS also may exhibit a defect in adrenal function, potentiating the hyperkalemic effect of TMP therapy." | 2.39 | Hyperkalemia and high-dose trimethoprim/sulfamethoxazole. ( Hsu, I; Wordell, CJ, 1995) |
| "The continuing growth of the acquired immunodeficiency syndrome (AIDS) epidemic has caused a parallel increase in patients with Pneumocystis carinii pneumonia (PCP)." | 2.38 | Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: pathophysiology, therapy, and prevention. ( Montgomery, AB, 1989) |
| "However, hypersensitivity pneumonitis from noninfectious etiologies, including environmental stimuli or drug exposure, is an unusual etiology of interstitial pneumonitis in HIV-infected patients." | 1.32 | Dapsone-induced hypersensitivity pneumonitis mimicking Pneumocystis carinii pneumonia in a patient with AIDS. ( Brown, KV; Hoteit, MA; King, MD; Ray, SM; Tobin-D'Angelo, MJ, 2004) |
| "We describe the course of 36 AIDS patients with cerebral toxoplasmosis and present a review of clinical signs, diagnosis, therapy, and survival times." | 1.31 | [HIV-associated cerebral toxoplasmosis -- review and retrospective analysis of 36 patients]. ( Evers, S; Fischer, A; Freund, M; Grüneberg, U; Happe, S; Heese, Ch; Husstedt, IW; Kloska, S; Reichelt, D, 2002) |
| "carinii prophylaxis before the onset of AIDS: Mycobacterium avium complex disease, which developed in 33." | 1.29 | Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. ( Anderson, R; Bacellar, H; Detels, R; Hoover, DR; Kaslow, RA; Phair, J; Saah, AJ, 1993) |
| "Pneumocystis carinii pneumonia has been the most common life-threatening opportunistic infection in patients with acquired immunodeficiency syndrome." | 1.29 | Dilemmas in the prophylaxis of Pneumocystis carinii pneumonia. ( Glatt, AE, 1994) |
| "The anticryptosporidial activity of four macrolides alone and in combination with other antimicrobial agents was investigated against ten clinical isolates of Cryptosporidium parvum recovered from stools of AIDS patients." | 1.29 | In-vitro activity of macrolides alone and in combination with artemisin, atovaquone, dapsone, minocycline or pyrimethamine against Cryptosporidium parvum. ( Cirioni, O; Giacometti, A; Scalise, G, 1996) |
| "The prevention of the occurrence and recurrence of PCP is a cornerstone in the treatment of patients infected with the human immunodeficiency virus." | 1.28 | A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. ( Beall, GN; Beck, K; Cox, PH; Martin, MA; Styer, CM, 1992) |
| "In 33 consecutive AIDS patients with a first episode of Pneumocystis carinii pneumonia (PCP) we evaluated treatment, outcome, recurrence rate and pyrimethamine as chemoprophylaxis in a 1-year follow-up." | 1.28 | Pneumocystis carinii pneumonia in Stockholm, Sweden: treatment, outcome, one-year-follow-up and pyrimethamine prophylaxis. ( Bergdahl, S; Julander, I; Lidman, C; Lundbergh, P; Ortqvist, A, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (38.71) | 18.7374 |
| 1990's | 31 (50.00) | 18.2507 |
| 2000's | 6 (9.68) | 29.6817 |
| 2010's | 1 (1.61) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vu, S | 1 |
| Iams, A | 1 |
| Blomkalns, A | 1 |
| Happe, S | 1 |
| Fischer, A | 1 |
| Heese, Ch | 1 |
| Reichelt, D | 1 |
| Grüneberg, U | 1 |
| Freund, M | 1 |
| Kloska, S | 1 |
| Evers, S | 1 |
| Husstedt, IW | 1 |
| Calista, D | 1 |
| Tobin-D'Angelo, MJ | 1 |
| Hoteit, MA | 1 |
| Brown, KV | 1 |
| Ray, SM | 1 |
| King, MD | 1 |
| Kazanjian, PH | 1 |
| Fisk, D | 1 |
| Armstrong, W | 2 |
| Shulin, Q | 1 |
| Liwei, H | 1 |
| Ke, Z | 1 |
| Meshnick, S | 1 |
| Poulsen, A | 1 |
| Hultberg, B | 1 |
| Thomsen, K | 1 |
| Wantzin, GL | 1 |
| Hsu, I | 1 |
| Wordell, CJ | 2 |
| Salmon-Ceron, D | 1 |
| Fontbonne, A | 1 |
| Saba, J | 1 |
| May, T | 1 |
| Raffi, F | 1 |
| Chidiac, C | 1 |
| Patey, O | 1 |
| Aboulker, JP | 1 |
| Schwartz, D | 1 |
| Vildé, JL | 1 |
| Wynn, RF | 1 |
| Laing, RB | 1 |
| Leen, CL | 1 |
| Hoover, DR | 1 |
| Saah, AJ | 1 |
| Bacellar, H | 1 |
| Phair, J | 1 |
| Detels, R | 1 |
| Anderson, R | 1 |
| Kaslow, RA | 1 |
| Pertel, P | 1 |
| Hirschtick, R | 1 |
| Glatt, AE | 1 |
| Mathews, LM | 1 |
| Mathews, PJ | 1 |
| Antinori, A | 1 |
| Murri, R | 1 |
| Ammassari, A | 1 |
| De Luca, A | 1 |
| Linzalone, A | 1 |
| Cingolani, A | 1 |
| Damiano, F | 1 |
| Maiuro, G | 1 |
| Vecchiet, J | 1 |
| Scoppettuolo, G | 1 |
| Bachmeyer, C | 1 |
| Aractingi, S | 1 |
| Weinberg, GA | 1 |
| Lee, BL | 3 |
| Safrin, S | 2 |
| Makrides, V | 1 |
| Gambertoglio, JG | 1 |
| Giacometti, A | 1 |
| Cirioni, O | 1 |
| Scalise, G | 1 |
| Gatti, G | 1 |
| Hossein, J | 1 |
| Malena, M | 1 |
| Cruciani, M | 1 |
| Bassetti, M | 1 |
| Guo, R | 1 |
| Thormann, W | 1 |
| Lauterberg, B | 1 |
| Ioannidis, JP | 1 |
| Lau, J | 1 |
| Payen, MC | 1 |
| De Wit, S | 1 |
| Sommereijns, B | 1 |
| Clumeck, N | 1 |
| Finkelstein, DM | 1 |
| Schoenfeld, DA | 1 |
| Kazanjian, P | 1 |
| Hossler, PA | 1 |
| Burman, W | 1 |
| Richardson, J | 1 |
| Lee, CH | 1 |
| Crane, L | 1 |
| Katz, J | 1 |
| Meshnick, SR | 1 |
| Gordeuk, VR | 1 |
| Delanghe, JR | 1 |
| Langlois, MR | 1 |
| Boelaert, JR | 1 |
| Martin, MA | 1 |
| Cox, PH | 1 |
| Beck, K | 1 |
| Styer, CM | 1 |
| Beall, GN | 1 |
| Mohle-Boetani, J | 1 |
| Akula, SK | 1 |
| Holodniy, M | 1 |
| Katzenstein, D | 1 |
| Garcia, G | 1 |
| Hardy, WD | 2 |
| Freedberg, KA | 1 |
| Tosteson, AN | 1 |
| Cohen, CJ | 1 |
| Cotton, DJ | 1 |
| Mallolas, J | 1 |
| Zamora, L | 1 |
| Gatell, JM | 1 |
| Miró, JM | 1 |
| Soriano, E | 1 |
| Costantino, M | 1 |
| Clotet, B | 1 |
| Sirera, G | 1 |
| Romeu, J | 1 |
| Gimeno, JM | 1 |
| Jou, A | 1 |
| Condom, MJ | 1 |
| Tor, J | 1 |
| Foz, M | 1 |
| Hughes, WT | 2 |
| Kennedy, W | 1 |
| Dugdale, M | 1 |
| Land, MA | 1 |
| Stein, DS | 1 |
| Weems, JJ | 1 |
| Palte, S | 1 |
| Lancaster, D | 1 |
| Gidan-Kovnar, S | 1 |
| Morrison, RE | 1 |
| Sattler, FR | 1 |
| Young, T | 1 |
| Bill, R | 1 |
| Boylan, CT | 1 |
| Mills, J | 5 |
| Kemper, CA | 1 |
| Tucker, RM | 1 |
| Lang, OS | 1 |
| Kessinger, JM | 1 |
| Greene, SI | 1 |
| Deresinski, SC | 1 |
| Stevens, DA | 1 |
| Crosby, WH | 1 |
| Medina, I | 3 |
| Leoung, G | 2 |
| Hopewell, PC | 3 |
| Lee, B | 1 |
| Modin, G | 1 |
| Benowitz, N | 1 |
| Wofsy, CB | 2 |
| Pinching, AJ | 1 |
| Helbert, M | 1 |
| Peddle, B | 1 |
| Robinson, D | 1 |
| Janes, K | 1 |
| Gor, D | 1 |
| Jeffries, DJ | 1 |
| Stoneham, C | 1 |
| Mitchell, D | 1 |
| Kocsis, AE | 1 |
| Lucas, CR | 1 |
| Sandland, AM | 1 |
| Mijch, A | 1 |
| Simpson, JM | 1 |
| Montgomery, AB | 2 |
| Lidman, C | 1 |
| Ortqvist, A | 1 |
| Lundbergh, P | 1 |
| Julander, I | 1 |
| Bergdahl, S | 1 |
| Girard, PM | 1 |
| Gonzalez, AH | 1 |
| Berlin, OG | 1 |
| Bruckner, DA | 1 |
| Benowitz, NL | 1 |
| Jacob, P | 1 |
| McKinsey, DS | 1 |
| Durfee, D | 1 |
| Kurtin, PJ | 1 |
| Hruza, GJ | 1 |
| Friedman-Kien, AE | 1 |
| Laubenstein, LJ | 1 |
| Wernz, JC | 1 |
| Lifshitz, MS | 1 |
| Rubinstein, P | 1 |
| Leoung, GS | 1 |
| Hughes, W | 1 |
| Wofsy, C | 2 |
| Kovacs, JA | 1 |
| Masur, H | 1 |
| Fischl, MA | 1 |
| Hauptman, SP | 1 |
| Green, ST | 1 |
| Goldberg, DJ | 1 |
| Leach, J | 1 |
| Christie, PR | 1 |
| Kennedy, DH | 1 |
| Reiter, WM | 1 |
| Cimoch, PJ | 1 |
| Aubry, P | 1 |
| Oddes, B | 1 |
| Edelson, PJ | 1 |
| Metroka, CE | 1 |
| Friedman-Kien, A | 1 |
| Catterall, JR | 1 |
| Potasman, I | 1 |
| Remington, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Neuroprotective Effect of Dapsone in Patients With Aneurysmal Subarachnoid Hemorrhage: Prospective, Randomized, Double-Blinded, Placebo-Controlled, Clinical Trial[NCT05131295] | Phase 3 | 49 participants (Actual) | Interventional | 2007-09-05 | Completed | ||
| Phase 1 Safety Run-in Study and Phase 1b Randomized, Double Blinded, Placebo Controlled Trial[NCT05695521] | Phase 1 | 66 participants (Anticipated) | Interventional | 2023-04-03 | Recruiting | ||
| A Randomized Study of the MitraClip Device in Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation[NCT01772108] | 42 participants (Actual) | Interventional | 2013-04-30 | Terminated (stopped due to As recruitment rate was lower than anticipated) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for dapsone and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
Hyperkalemia and high-dose trimethoprim/sulfamethoxazole.
Topics: Acquired Immunodeficiency Syndrome; Clinical Trials as Topic; Dapsone; Drug Therapy, Combination; Hu | 1995 |
Iron status and the outcome of HIV infection: an overview.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Anti-Infective Agents; be | 2001 |
The sulfone syndrome in a patient receiving dapsone prophylaxis for Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Drug Hypersensitivity; Humans; Male; Opportunist | 1992 |
Prophylaxis of AIDS-related opportunistic infections (OIs). Current status and future strategies.
Topics: Acquired Immunodeficiency Syndrome; Aerosols; Animals; Cryptococcosis; Cytomegalovirus Infections; D | 1991 |
[Pneumocystis carinii pneumonia in HIV infections. Committee of the 1st Consensus Conference of anti-infectious therapy organized in May 1990 in Paris by the Société de Pathologie Infectieuse de Langue Française].
Topics: Acquired Immunodeficiency Syndrome; Aerosols; Clinical Protocols; Dapsone; France; HIV Infections; H | 1990 |
Recent developments in the therapy and management of Pneumocystis carinii pneumonia in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Dapsone; Drug Therapy, Combination; Humans; Pentamidine; Pneumon | 1989 |
Prophylaxis of AIDS-related opportunistic infections (OIs).
Topics: Acquired Immunodeficiency Syndrome; Cryptococcosis; Cytomegalovirus Infections; Dapsone; Drug Combin | 1989 |
Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: pathophysiology, therapy, and prevention.
Topics: Acquired Immunodeficiency Syndrome; Aerosols; Dapsone; Diet; Drug Combinations; Humans; Oxygen Inhal | 1989 |
Pneumocystis carinii pneumonia: therapy and prophylaxis.
Topics: Acquired Immunodeficiency Syndrome; Anti-Bacterial Agents; Dapsone; Drug Combinations; Drug Therapy, | 1988 |
Treatment and prophylaxis of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Adrenal Cortex Hormones; Antiprotozoal Agents; Clinical Trials a | 1988 |
Prevention of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Aerosols; Dapsone; Drug Combinations; Humans; Pentamidine; Pneum | 1988 |
15 trials available for dapsone and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. Study Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aerosols; AIDS-Related Opportunistic Infections; Dapsone; | 1995 |
Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Animals; Anti-Infe | 1995 |
Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Drug Combinations; Humans; Male; Trimethoprim; Z | 1996 |
Penetration of dapsone into cerebrospinal fluid of patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Female; Humans; Male; Middle Aged; Pneumonia, Pn | 1997 |
A controlled trial of dapsone versus pyrimethamine-sulfadoxine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; AIDS-Related Opportunistic Infections; Anti-Infecti | 1997 |
Combining mortality and longitudinal measures in clinical trials.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Anti-Infective Agents; Antifungal Agents; Candi | 1999 |
Combining mortality and longitudinal measures in clinical trials.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Anti-Infective Agents; Antifungal Agents; Candi | 1999 |
Combining mortality and longitudinal measures in clinical trials.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Anti-Infective Agents; Antifungal Agents; Candi | 1999 |
Combining mortality and longitudinal measures in clinical trials.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Anti-Infective Agents; Antifungal Agents; Candi | 1999 |
Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Dihydropteroate Synthase; Female; Humans; Male; | 2000 |
Prophylaxis of AIDS-related opportunistic infections (OIs). Current status and future strategies.
Topics: Acquired Immunodeficiency Syndrome; Aerosols; Animals; Cryptococcosis; Cytomegalovirus Infections; D | 1991 |
Low-dose co-trimoxazole, aerosolised pentamidine, or dapsone plus pyrimethamine for prevention of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Dapsone; Follow-Up Studies; Humans; Pentamidine; Pneumonia, Pneu | 1991 |
Prevention of Pneumocystis carinii pneumonitis in AIDS patients with weekly dapsone.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Dapsone; Drug Administration Schedule; Hum | 1990 |
Dapsone as a single agent is suboptimal therapy for Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Humans; Male; Pneumonia, Pneumocystis; Prospecti | 1991 |
Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Chemical and Drug Induced Liver Inj | 1990 |
Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions.
Topics: Acetylation; Acquired Immunodeficiency Syndrome; Adult; Dapsone; Drug Interactions; Drug Therapy, Co | 1989 |
Treatment and prophylaxis of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Adrenal Cortex Hormones; Antiprotozoal Agents; Clinical Trials a | 1988 |
Pneumocystis carinii pneumonia in the patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Animals; Bronchoscopy; Clinical Trials as Topic; Dapsone; Drug C | 1985 |
38 other studies available for dapsone and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
Neutropenia, Hypoxia, and the Complexities of Emergency Medicine: A Case of Dapsone-Induced Methemoglobinemia.
Topics: Acquired Immunodeficiency Syndrome; Anti-Infective Agents; Dapsone; Emergency Service, Hospital; Enz | 2019 |
[HIV-associated cerebral toxoplasmosis -- review and retrospective analysis of 36 patients].
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; AIDS-Related Opportunistic Infections; Antiretrovir | 2002 |
Subcorneal pustular dermatosis in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiretroviral Therapy, Highly Active; Biopsy, Needle; Da | 2003 |
Dapsone-induced hypersensitivity pneumonitis mimicking Pneumocystis carinii pneumonia in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alveolitis, Extrinsic Allergic; Dapsone; Diagnosis, Diffe | 2004 |
Increase in prevalence of Pneumocystis carinii mutations in patients with AIDS and P. carinii pneumonia, in the United States and China.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Infective Age | 2004 |
Regression of Kaposi's sarcoma in AIDS after treatment with dapsone.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Homosexuality; Humans; Male; Sarcoma, Kaposi; Sk | 1984 |
Drugs for AIDS and associated infections.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifunga | 1995 |
Case report of dapsone-related thrombocytosis in an AIDS patient.
Topics: Acquired Immunodeficiency Syndrome; Adult; Asthma; Dapsone; Humans; Male; Thrombocytosis | 1995 |
Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Candidiasis; CD4-Positive | 1993 |
Adverse reactions to dapsone in persons infected with human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Drug Tolerance; Humans; Male; Pneumonia, Pneumoc | 1994 |
Dilemmas in the prophylaxis of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Clindamycin; Dapso | 1994 |
Actionstat. Methemoglobinemia.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Emergency Nursing; Humans; Male; Methemoglobinem | 1995 |
Erythema elevatum diutinum with HIV-2 infection.
Topics: Acquired Immunodeficiency Syndrome; Anti-Infective Agents; Dapsone; Erythema; Hand Dermatoses; HIV-2 | 1996 |
Iron overload as a mechanism for the lowered survival in AIDS patients receiving dapsone-iron protoxalate for secondary prophylaxis of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Da | 1996 |
In-vitro activity of macrolides alone and in combination with artemisin, atovaquone, dapsone, minocycline or pyrimethamine against Cryptosporidium parvum.
Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Artemisin | 1996 |
Relationship between high incidence of adverse dapsone reactions and slow acetylate phenotype or low plasma/lymphocyte glutathione level.
Topics: Acetylation; Acquired Immunodeficiency Syndrome; Adult; Anti-Infective Agents; Caffeine; Chromatogra | 1996 |
Heterogeneity of the baseline risk within patient populations of clinical trials: a proposed evaluation algorithm.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Algorithms; Anti-HIV Agen | 1998 |
A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Dapsone; Drug Administration Schedule; Drug Therapy | 1992 |
Primary prophylaxis for Pneumocystis carinii pneumonia in HIV-infected people with CD4 counts below 200/mm3: a cost-effectiveness analysis.
Topics: Acquired Immunodeficiency Syndrome; Aerosols; Antiviral Agents; CD4-Positive T-Lymphocytes; Cost-Ben | 1991 |
[Some aspects of the treatment of HIV infection].
Topics: Acquired Immunodeficiency Syndrome; Clindamycin; Dapsone; HIV Infections; Humans; Primaquine; Trimet | 1991 |
Twice-weekly dapsone-pyrimethamine for preventing PCP and cerebral toxoplasmosis.
Topics: Acquired Immunodeficiency Syndrome; Brain Diseases; Dapsone; Drug Administration Schedule; Drug Ther | 1991 |
Low-dose dapsone prophylaxis of Pneumocystis carinii pneumonia in AIDS and AIDS-related complex.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; AIDS-Related Complex; Costs and Cos | 1990 |
Megaloblastic pancytopenia associated with dapsone and trimethoprim treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Anemia, Macrocytic; Anemia, Megaloblastic; Dapsone; Humans; Leuc | 1990 |
Clinical experience with zidovudine for patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; AIDS-Related Complex; Bone Marrow; Brain Diseases; Da | 1989 |
Primary dapsone chemoprophylaxis for Pneumocystis carinii pneumonia in immunocompromised patients infected with the human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; AIDS-Related Complex; Dapsone; Huma | 1989 |
Pneumocystis carinii pneumonia in Stockholm, Sweden: treatment, outcome, one-year-follow-up and pyrimethamine prophylaxis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Dapsone; Drug Evaluation; Drug Therapy, Combination | 1989 |
[Treatment and prevention of pneumocystosis].
Topics: Acquired Immunodeficiency Syndrome; Adrenal Cortex Hormones; Anti-Bacterial Agents; Dapsone; Humans; | 1989 |
In-vitro activity of dapsone and two potentiators against Mycobacterium avium complex.
Topics: Acquired Immunodeficiency Syndrome; Anti-Bacterial Agents; Dapsone; Drug Synergism; Humans; Microbia | 1989 |
Megaloblastic pancytopenia associated with dapsone and trimethoprim treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Drug Therapy, Combination; Humans; Male; Pancyto | 1989 |
Dapsone for AIDS-associated Kaposi's sarcoma.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Humans; Male; Middle Aged; Sarcoma, Kaposi | 1985 |
Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Bronchoscopy; Dapsone; Drug Eruptions; Drug Therapy, Combination | 1986 |
Treatment of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Dapsone; Drug Combinations; Folic Acid Antagonists; Humans; Meth | 1987 |
Treatment of Pneumocystis carinii pneumonia in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adrenal Cortex Hormones; Adult; Anti-Infective Agents; Dapsone; | 1988 |
Dapsone treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Dapsone; Drug Therapy, Combination; Humans; M | 1988 |
AIDS-related Pneumocystis carinii pneumonia successfully treated with dapsone-trimethoprim.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Drug Therapy, Combination; Humans; Male; Pneumon | 1988 |
Dapsone-induced methemoglobinemia in a patient with P. carinii pneumonia and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Dapsone; Humans; Male; Methemoglobinemia; Pneumonia, Pneumocysti | 1987 |
[Kaposi's sarcoma associated with AIDS].
Topics: Acquired Immunodeficiency Syndrome; Cobalt Radioisotopes; Dapsone; Humans; Interferon Type I; Sarcom | 1986 |
Dapsone, trimethoprim-sulfamethoxazole, and the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Dapsone; Drug Combinations; Humans; Pneumonia, Pneumocystis; Sul | 1985 |